To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Pertuzumab (also called 2C4, formerly known as Omnitarg) is a monoclonal antibody. The first of its class in a line of agents called "HER dimerization inhibitors". By binding to HER2, it inhibits the dimerization of HER2 with other HER receptors, which is hypothesized to result in slowed tumor growth. Omnitarg is currently being developed by Genentech.
Additional recommended knowledge
Early clinical trials of pertuzumab in prostate, breast, and ovarian cancers have been met with limited success.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Pertuzumab". A list of authors is available in Wikipedia.|